Immunotherapy + Chemoradiotherapy Could Lead to More Effective Treatment of Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Dr. Xuefeng Leng from Sichuan Cancer, Hospital & Institute located in Chengdu, China present in this MEDtalks the results from his late breaking abstract presented at ACCO GI 2025. This is the first three-arm randomized trial to evaluate immunotherapy-based combination treatment modalities against a standard neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.
In the MEDtalk Dr. Xuefeng Leng emphasize that the results of the study show that immunotherapy + chemoradiotherapy could lead to more effective treatment of resectable locally advanced esophageal squamous cell carcinoma.